In the Know: Optimized Management of
Asparaginase Therapy in ALL
Expert Roundtable
The certification period for this program has expired.
No credit will be offered beyond the program dates noted on the bottom of this page.
Jointly provided by Integrity Continuing Education, Inc. and Bonum Continuing Education LLC.
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Program Overview
Current first-line treatment of acute lymphoblastic leukemia (ALL) comprises induction, consolidation, intensification, and maintenance chemotherapy. Asparaginase is a critical component during induction, consolidation and intensification in pediatric and adult/young adult populations leading to improvements in event-free and overall survival. Yet the toxicity profile of asparaginase and drug-shortages both contribute to insufficient exposure to asparaginase and suboptimal outcomes in ALL. With the recent approval of asparaginase erwinia chrysanthemi (recombinant)- rywn (ERW-rywn), health care professionals (HCPs) treating patients with ALL need to be informed of efficacy and safety data supporting ERW-rywn’s use. Thus, this CME-certified, Twitter-based program will review the dosing, efficacy, and safety of ERW-rywn and compare this therapy to ERW.
Faculty
Ryan D. Cassaday, MD
Associate Professor, Division of Hematology,
University of Washington School of Medicine
Associate Professor, Clinical Research Division,
Fred Hutchinson Cancer Research Center
Attending Physician, Hematologic Malignancies Program, Seattle Cancer Care Alliance
Seattle, WA
Lori Muffly, MD, MS
Associate Professor of Medicine
Division of Blood and Marrow Transplantation & Cellular Therapy
Stanford University
Stanford, CA
Luke Maese, DO
Associate Professor
University of Utah School of Medicine
Huntsman Cancer Institute
Primary Children's Hospital
Salt Lake City, UT
Target Audience
This education activity has been designed to meet the needs of:
Hematologists, medical oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other HCPs interested in the treatment of patients with ALL
Learning Objectives
Upon completion of this educational activity, participants should be able to:
Articulate the significance of nonadherence to the dosing of asparaginase it the management of acute lymphoblastic leukemia
Based on patient specific factors and clinical guidelines, discern when a patient should permanently discontinue, temporarily hold, or continue with pegasparaginase, or change to an Erwinia asparaginase product
Distinguish between allergic and nonallergic infusion reaction with the use of postdosing therapeutic drug monitoring to discern the need to switch to an Erwinia asparaginase product
Compare asparaginase erwinia chrysanthemi (recombinant)-rywn (ERW-rywn) with asparaginase erwinia chrysanthemi (ERW) based on efficacy, toxicity, manufacturing, dosing and administration
Directions to Learner
There are no fees for participating and receiving CME credit for this activity. During the period of April 28, 2022 through April 28, 2023, participants must:
Read the learning objectives and faculty disclosures
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form
A statement of credit will be issued only upon successful completion (75% passing score) and receipt of the activity posttest and evaluation form. Certificates will be sent via email within four weeks of receipt of a completed evaluation form.
Accreditation
Physician Continuing Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Integrity Continuing Education, Inc. and Bonum Continuing Education LLC.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Integrity Continuing Education, Inc. designates this Other activity (multi-channel video and discussion) for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
-
Ryan D. Cassaday, MD
Consulting: Amgen, Kite/Gilead, Pfizer
Contracted Research: Amgen, Kite/Gilead, Merck, Pfizer, Servier, Vanda Pharmaceuticals
Speaker’s Bureau: Kite/Gilead, Pfizer
DSMB Member: Pepromene BioLori Muffly, MD, MS
Consulting: Amgen, Astellas, CTI Biopharma, Kite, Medexus, Pfizer
Contracted Research: Adaptive, Astellas, Bristol Myers Squibb, Jasper, Kite
Speaker’s Bureau: AdaptiveLuke Maese, DO
Consulting: Jazz Pharmaceuticals
Speakers’ Bureau: Jazz Pharmaceuticals -
Bonum Continuing Education LLC staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Minimum System Requirements
Media: Internet
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
• Adobe® Flash® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus
For optimal performance, the use of Internet Explorer below 8 is not recommended
Privacy Policy
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)
Contact Information
For information about ACCME certification of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.
Release date: April 28, 2022
Expiration date: April 28, 2023
Estimated time to complete activity: 60 minutes